Description
Buy 1 Get 1 Free CJC-1295 NO-DAC (MOD GRF 1-29) 2mg :
| Unit Size | 2 mg/vial |
| Unit Quantity | 1 vial |
| Purity (Mass Spectrometry and UV) | 99.18% |
| Sequence | H-Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala- Gln-Leu- Ser-Ala-Arg-Lys-Leu–Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2 |
| Molecular Formula | C152H252N44O42 |
| Appearance | Lyophilized White Powder |
| Source | Chemical Synthesis |
| Storage | Lyophilized CJC-1295 NO-DAC is stable at room Temperature for 90 days, however it is best to store in a freezer below – 8c for any extended period of time. |
| Terms | The products we offer are intended for laboratory research use only. Please familiarize yourself with our terms of service prior to ordering. |
CJC-1295 NO-DAC 2mg (MOD GRF 1-29)
View Research Overview & References
CJC-1295 NO-DAC is a synthetic peptide studied in laboratory research, featuring the first 29 amino acids of growth hormone-releasing hormone (GHRH), also called modified growth releasing factor 1-29 (MOD GRF 1-29).1 This peptide has a molecular weight of approximately 3.4 kDa and retains structural features of GHRH, making it a subject of interest for in vitro and in vivo (animal) studies on growth and development.2
The unique feature of CJC-1295 NO-DAC is the absence of a Drug Affinity Complex (DAC), which is associated with a more physiological response profile in controlled lab environments. Designed using a Human GRF template, this peptide incorporates modified amino acids that enhance stability, such as substituting the first two amino acids to reduce peptidase-mediated degradation in cell cultures.3,4 With an extended half-life of around 30 minutes, CJC-1295 demonstrates improved stability over unmodified GHRH in laboratory research settings.3
Animal Model Research
In animal model studies, CJC-1295 has been examined for its impacts on growth and metabolic markers. For example, in a study of GHRH knockout mice, researchers administered CJC-1295 over a five-week period and observed body weight and length comparable to control groups.1 Separately, CJC-1295 has been studied in obese rat models in the context of growth hormone research, broadening its relevance to metabolic and growth-related research topics.5 Studies also suggest that MOD GRF has distinct pharmacokinetic and pharmacodynamic properties compared to endogenous GHRH, which researchers have examined in laboratory studies of growth and metabolic regulation.4
Product Information
CJC-1295 NO-DAC is provided as a 2 mg lyophilized powder in a vial, intended strictly for in vitro and in vivo (animal) laboratory research and not suitable for human or animal use outside controlled research settings.
References
1. Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006 Dec;291(6):E1290-4.
2. Matsoukas MT, Spyroulias GA. Dynamic properties of the growth hormone-releasing hormone receptor (GHRHR) and molecular determinants of GHRH binding. Mol Biosyst. 2017 Jun 27;13(7):1313-1322.
3. Campbell RM, Stricker P, Miller R, Bongers J, Liu W, Lambros T, Ahmad M, Felix AM, Heimer EP. Enhanced stability and potency of novel growth hormone-releasing factor (GRF) analogues derived from rodent and human GRF sequences. Peptides. 1994;15(3):489-95.
4. Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, Paradis V, van Wyk P, Pham K, Bridon DP. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005 Jul;146(7):3052-8.
5. Renier G, Gaudreau P, Deslauriers N, Petitclerc D, Brazeau P. Dynamics of the GRF-induced GH response in genetically obese Zucker rats: influence of central and peripheral factors. Regul Pept. 1990 Mar 27;28(1):95-106.
